MicroRNA-133a Suppresses Colorectal Cancer Cell Invasion by Targeting Fascin1

Overview

Journal Oncol Lett

Specialty Oncology

Date 2015 Jan 27

PMID 25621061

Citations 24

Authors

Keyan Zheng

Weicheng Liu

Ye Liu

Congqing Jiang

Qun Qian

Affiliations

Soon will be listed here.

Abstract

MicroRNAs (miRs) are a type of small non-coding RNA molecule that are involved in gene silencing and the regulation of cancer progression; miR-133a in particular has been implicated in colorectal cancer, although its specific role and underlying mechanism have yet to be determined. In the present study, the expression level of miR-133a was significantly downregulated in a number of colorectal cancer cell lines, as well as in colorectal cancer tissues compared with the normal adjacent tissues. Furthermore, the Fascin1 (FSCN1) gene was identified as a direct target of miR-133a, and the protein expression level of FSCN1 was negatively regulated by miR-133a in colorectal cancer cells. Additionally, restoration of miR-133a expression and downregulation of FSCN1 protein expression suppressed colorectal cancer cell invasion, while overexpression of FSCN1 reversed the inhibitory effect of miR-133a upregulation on colorectal cancer cell invasion. Thus, the present data indicates that miR-133a may at least partially suppress colorectal cancer cell invasion, possibly via the inhibition of FSCN1 expression. The present study highlights the important role of miR-133a in the progression of colorectal cancer.

Citing Articles

FSCN1 acts as a promising therapeutic target in the blockade of tumor cell motility: a review of its function, mechanism, and clinical significance.

Li Z, Shi J, Zhang N, Zheng X, Jin Y, Wen S J Cancer. 2022; 13(8):2528-2539.

PMID: 35711849 PMC: 9174856. DOI: 10.7150/jca.67977.

Emerging Role of Fascin-1 in the Pathogenesis, Diagnosis, and Treatment of the Gastrointestinal Cancers.

Ristic B, Kopel J, Sherazi S, Gupta S, Sachdeva S, Bansal P Cancers (Basel). 2021; 13(11).

PMID: 34064154 PMC: 8196771. DOI: 10.3390/cancers13112536.

Fascin actin-bundling protein 1 in human cancer: promising biomarker or therapeutic target?.

Liu H, Zhang Y, Li L, Cao J, Guo Y, Wu Y Mol Ther Oncolytics. 2021; 20:240-264.

PMID: 33614909 PMC: 7873579. DOI: 10.1016/j.omto.2020.12.014.

Emerging roles of MiR-133a in human cancers.

Hua Y, Xu W, Li H, Xia M J Cancer. 2021; 12(1):198-206.

PMID: 33391416 PMC: 7738817. DOI: 10.7150/jca.48769.

The significance of microRNA deregulation in colorectal cancer development and the clinical uses as a diagnostic and prognostic biomarker and therapeutic agent.

Ahadi A Noncoding RNA Res. 2020; 5(3):125-134.

PMID: 32954092 PMC: 7476809. DOI: 10.1016/j.ncrna.2020.08.003.

References

Dong Y, Zhao J, Wu C, Zhang L, Liu X, Kang W . Tumor suppressor functions of miR-133a in colorectal cancer. Mol Cancer Res. 2013; 11(9):1051-60. DOI: 10.1158/1541-7786.MCR-13-0061. View

Wu Z, Wang C, Xiang R, Liu X, Ye S, Yang X . Loss of miR-133a expression associated with poor survival of breast cancer and restoration of miR-133a expression inhibited breast cancer cell growth and invasion. BMC Cancer. 2012; 12:51. PMC: 3297527. DOI: 10.1186/1471-2407-12-51. View

Qian B, Nag S, Su Y, Voruganti S, Qin J, Zhang R . miRNAs in cancer prevention and treatment and as molecular targets for natural product anticancer agents. Curr Cancer Drug Targets. 2013; 13(5):519-41. DOI: 10.2174/15680096113139990031. View

Khare S, Verma M . Epigenetics of colon cancer. Methods Mol Biol. 2012; 863:177-85. DOI: 10.1007/978-1-61779-612-8_10. View

Machesky L, Li A . Fascin: Invasive filopodia promoting metastasis. Commun Integr Biol. 2010; 3(3):263-70. PMC: 2918773. DOI: 10.4161/cib.3.3.11556. View

Arndt G, Dossey L, Cullen L, Lai A, Druker R, Eisbacher M . Characterization of global microRNA expression reveals oncogenic potential of miR-145 in metastatic colorectal cancer. BMC Cancer. 2009; 9:374. PMC: 2770572. DOI: 10.1186/1471-2407-9-374. View

Ye J, Cao J . MicroRNAs in colorectal cancer as markers and targets: Recent advances. World J Gastroenterol. 2014; 20(15):4288-99. PMC: 3989964. DOI: 10.3748/wjg.v20.i15.4288. View

Siegel R, DeSantis C, Jemal A . Colorectal cancer statistics, 2014. CA Cancer J Clin. 2014; 64(2):104-17. DOI: 10.3322/caac.21220. View

Fu H, Hu Z, Wen J, Wang K, Liu Y . TGF-beta promotes invasion and metastasis of gastric cancer cells by increasing fascin1 expression via ERK and JNK signal pathways. Acta Biochim Biophys Sin (Shanghai). 2009; 41(8):648-56. DOI: 10.1093/abbs/gmp053. View

10.

Wang L, Hsiao T, Hong T, Chen H, Kao S, Wang W . MicroRNA-133a suppresses multiple oncogenic membrane receptors and cell invasion in non-small cell lung carcinoma. PLoS One. 2014; 9(5):e96765. PMC: 4016005. DOI: 10.1371/journal.pone.0096765. View

11.

Qiu T, Zhou X, Wang J, Du Y, Xu J, Huang Z . MiR-145, miR-133a and miR-133b inhibit proliferation, migration, invasion and cell cycle progression via targeting transcription factor Sp1 in gastric cancer. FEBS Lett. 2014; 588(7):1168-77. DOI: 10.1016/j.febslet.2014.02.054. View

12.

Park S, Song J, Kim Y, Heo J, Kang H, Kim G . Fascin1 expression in high-grade serous ovarian carcinoma is a prognostic marker and knockdown of fascin1 suppresses the proliferation of ovarian cancer cells. Int J Oncol. 2014; 44(3):637-46. PMC: 3928475. DOI: 10.3892/ijo.2013.2232. View

13.

Akanuma N, Hoshino I, Akutsu Y, Murakami K, Isozaki Y, Maruyama T . MicroRNA-133a regulates the mRNAs of two invadopodia-related proteins, FSCN1 and MMP14, in esophageal cancer. Br J Cancer. 2013; 110(1):189-98. PMC: 3887287. DOI: 10.1038/bjc.2013.676. View

14.

Kano M, Seki N, Kikkawa N, Fujimura L, Hoshino I, Akutsu Y . miR-145, miR-133a and miR-133b: Tumor-suppressive miRNAs target FSCN1 in esophageal squamous cell carcinoma. Int J Cancer. 2011; 127(12):2804-14. DOI: 10.1002/ijc.25284. View

15.

Guo J, Xia B, Meng F, Lou G . miR-133a suppresses ovarian cancer cell proliferation by directly targeting insulin-like growth factor 1 receptor. Tumour Biol. 2013; 35(2):1557-64. DOI: 10.1007/s13277-013-1215-z. View

16.

Chiyomaru T, Enokida H, Tatarano S, Kawahara K, Uchida Y, Nishiyama K . miR-145 and miR-133a function as tumour suppressors and directly regulate FSCN1 expression in bladder cancer. Br J Cancer. 2010; 102(5):883-91. PMC: 2833258. DOI: 10.1038/sj.bjc.6605570. View

17.

Tsai W, Chao Y, Sheu L, Chang J, Nieh S, Jin J . Overexpression of fascin-1 in advanced colorectal adenocarcinoma: tissue microarray analysis of immunostaining scores with clinicopathological parameters. Dis Markers. 2007; 23(3):153-60. PMC: 3850856. DOI: 10.1155/2007/685163. View

18.

Chan C, Jankova L, Fung C, Clarke C, Robertson G, Chapuis P . Fascin expression predicts survival after potentially curative resection of node-positive colon cancer. Am J Surg Pathol. 2010; 34(5):656-66. DOI: 10.1097/PAS.0b013e3181db36c0. View

19.

Fujiwara T, Katsuda T, Hagiwara K, Kosaka N, Yoshioka Y, Takahashi R . Clinical relevance and therapeutic significance of microRNA-133a expression profiles and functions in malignant osteosarcoma-initiating cells. Stem Cells. 2014; 32(4):959-73. DOI: 10.1002/stem.1618. View

20.

Fabbri M, Calore F, Paone A, Galli R, Calin G . Epigenetic regulation of miRNAs in cancer. Adv Exp Med Biol. 2012; 754:137-48. DOI: 10.1007/978-1-4419-9967-2_6. View